The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.

Video on Dry Eyeeye_pic.jpg

In recent years the nosology of Dry Eye has greatly changed. Professor Baudouin, MD, PhD from National Ophthalmologiy Hospital XV-XX, Vision Institute of Paris explains through this didactic video the complexity of the Dry Eye disease. Moving beyond the simple name of Dry Eye syndrome, we now consider the condition to be Dry Eye disease, insisting on the lack of tears, the lacrimal inflammation and hyperevaporation leading to self-sustaining loops of neurogenic and palpebral inflammations.

View the video


Viscoelastic gel for use in ocular surgery

VISIOL® is a hyaluronic-acid containing viscoelastic gel with pseudoplastic properties for use as a surgical aid in ocular surgery.

Hyaluronic acid (HA) is a natural biopolymer already present in the body including the eyes.

VISIOL® contains mannitol to help scavenge free radicals that are produced during phacoemulsification of the nucleus. Mannitol helps maintain the rheological properties of HA during phacoemulsification in cataract surgery, thus providing enhanced protection to the endothelium especially in patients with a hard nucleus.

VISIOL® combines optimum cohesive and dispersive properties and thus can be used throughout the surgery. Its specific characteristics provide an optimum protection for the ocular tissues during various ocular surgery procedures such as cataract surgery, intraocular lens implantation, corneal transplant surgery and glaucoma filtering surgery.

VISIOL® is designed for the hand of the surgeon and the eye of the patient.

 visiol_web.jpg pdf VISIOL® leaflet
trb_lock.gif Doctor information

  • English